Author: Michael Cameron ; Virginia Takahashi ; Qin Liu ; Peter Chase ; Peter Hodder ; Smitha Kota ; William Roush ; Becky A. Mercer ; A. Donny Strosberg ; Franck Madoux

Over three million Americans are infected by the Hepatits C Virus (HCV) virus 2 which is particularly lethal for Acquired Immunodeficiency Syndrome (AIDS) patients, of whom increasing numbers are co-infected with Human Immunodeficiency Virus infection (HIV) and HCV. There is no vaccine, and the only available treatment, based on a combination of interferon and ribavirin, cures less than half of the patients. One of the important structural proteins of HCV is the core protein. HCV core has many reported functions in the host cells, but its main purpose for the virus is to enclose and thereby protect the HCV Ribonucleic acid (RNA) genome during disease transmission. The conserved nature of HCV and absence of a vaccine, along with studies demonstrating that core contributes to host cell oncogenesis, apoptosis inhibition, and suppression of host T cell responses, support a role for core as a major pathogenic component of HCV. As a result, the identification of specific inhibitors of HCV core dimerization may provide tools for inhibiting HCV assembly without host cell effects. Several studies identify HCV capsid assembly as an appropriate target for chemotherapeutic intervention of HCV infections. Thus, this High Throughput Screen (HTS) program was initiated to identify small molecules that inhibit HCV core protein dimerization. Following an HTS effort and several rounds of medicinal chemistry, we have identified compound CID 49800087 as inhibitor probe (ML322) belonging to the [1,2,4]triazolo[1,5-a]pyrimidin-2-yl scaffold. The probe inhibits dimerization of core proteins in biochemical Alphascreen assays (IC50 = 8.4 μM; 51% inhibition at 15 μM). Using quantitative polymerase chain reactions (QPCR) the probe was shown to reduce levels of total HCV RNA in infected cells (IC50 = 1.8 μM) and significantly reduces levels of infectious HCV RNA in cells treated with HCV-containing culture supernatants (IC50 = 2 nM). Profiling revealed that probe ML322 lacks activity against a panel of 63 receptors, transporters, and ion channels (Ricerca). Modest activity was detected at muscarinic M1-3, adrenergic alpha, and dopamine transporter (DAT). Critically, probe ML322 is not cytotoxic against the Huh7.5 liver cell line used for the infectivity assays (CC50 = 33 μM). This novel probe represents an exciting tool for use in basic HCV research to elucidate the mechanisms by which core-core dimerization contributes to HCV nucleocapsid formation, HCV infection, and liver cancers associated with HCV.

100 Deals associated with ML322

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hepatitis C	Preclinical	United States	The Scripps Research Institute	13 May 2014

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

ML322

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation